SCHEMBL353171

SCHEMBL353171

Cc1cc(=O)oc(C)c1C(=O)N(C)Cc1csc(NC(=O)NCc2ccc(Cl)s2)n1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.38
CYP1A2 P05177 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP2C9 P11712 4/20 0.37
CYP2C19 P33261 2/20 0.37
KMT2A Q03164 5/20 0.36
MEN1 O00255 4/20 0.36
F10 P00742 1/20 0.36
LMNA P02545 1/20 0.35
KDM4E B2RXH2 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 3/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 2/20 0.34
ROCK2 O75116 1/20 0.34
ROCK1 Q13464 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352384 0.87 ALDH1A1 (0.37) ALDH1A1CYP1A2L3MBTL1CYP2C9CYP2C19
SCHEMBL352359 0.84 LMNA (0.41) ALDH1A1CYP1A2CYP2C9CYP2C19KMT2A
SCHEMBL355313 0.83 ROCK2 (0.49) ALDH1A1CYP1A2L3MBTL1CYP2C9CYP2C19
SCHEMBL353060 0.82 THRB (0.43) KMT2AMEN1F10LMNAPOLB
SCHEMBL353896 0.81 KMT2A (0.37) ALDH1A1KMT2AMEN1F10LMNA
SCHEMBL355250 0.81 KMT2A (0.38) ALDH1A1KMT2AMEN1F10LMNA
SCHEMBL352961 0.81 KMT2A (0.37) ALDH1A1L3MBTL1KMT2AMEN1F10
SCHEMBL353525 0.81 RAB9A (0.38) ALDH1A1KMT2AMEN1F10LMNA
SCHEMBL352881 0.79 KMT2A (0.40) ALDH1A1L3MBTL1KMT2AMEN1F10
SCHEMBL354863 0.79 KMT2A (0.39) ALDH1A1KMT2AMEN1F10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP claimed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US claimed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO claimed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 EP disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA ALDH1A1 2806/4885CYP1A2 2181/4885L3MBTL1 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.